|
" Novel anticancer drug protocols / "
edited by John K. Buolamwini and Alex A. Adjei.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
1047452
|
| Doc. No
|
:
|
b801822
|
| Title & Author
|
:
|
Novel anticancer drug protocols /\ edited by John K. Buolamwini and Alex A. Adjei.
|
| Publication Statement
|
:
|
Totowa, NJ :: Humana Press,, ©2003.
|
| Series Statement
|
:
|
Methods in molecular medicine ;; 85
|
| Page. NO
|
:
|
1 online resource (xv, 355 pages) :: illustrations (some color)
|
| ISBN
|
:
|
0896039633
|
|
|
:
|
: 1280842571
|
|
|
:
|
: 1592593801
|
|
|
:
|
: 6610842574
|
|
|
:
|
: 9780896039636
|
|
|
:
|
: 9781280842573
|
|
|
:
|
: 9781592593804
|
|
|
:
|
: 9786610842575
|
|
|
:
|
9781489938398
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index.
|
| Contents
|
:
|
Overview of novel anticancer drug targets / J.K. Buolamwini and H. Assefa -- Biomarker assays for phosphorylated MAP kinase. Their utility for measurement of MEK inhibition / J.S. Sebolt-Leopold [and others] -- Assays for cyclin-dependent kinase inhibitors / A.M. Senderowicz and T. Lahusen -- Identifying inhibitors of ATM and ATR kinase activities / J.N. Sarkaria -- The rat aortic ring assay for in vitro study of angiogenesis / R.S. Go and W.G. Owen -- Real time in vivo quantitation of tumor angiogenesis / G.I. Frost and P. Borgstrom -- Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development / E. Olaso and F. Vidal-Vanaclocha -- Cell motility, adhesion, homing, and migration assays in the studies of tyrosine kinases / M. Sattler, E. Quackenbush and R. Salgia -- Inflammatory response of tumor-activated hepatic sinusoidal endothelium as a target for the screening of metastasis chemopreventive drugs / L. Mendoza and F. Vidal-Vanaclocha -- Binding assay for selectins / J. Zhang and M.N. Fukuda -- Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine / J.A. Hank [and others] -- Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples / S.N. Malik [and others] -- Immunohistochemical assays of farnesyltransferase inhibition in patient samples / A.A. Adjei -- Assays for HSP90 and inhibitors / W. Aherne [and others] -- Assays for proteasome inhibition / P.J. Elliott [and others] -- The mammalian two-hybrid assay for detection of coactivator-nuclear receptor interactions / C.M. Tyree and K. Klausing -- Preparation of DNA-protein complexes suitable for spectroscopic analysis / N. Neamati, M. Murthy and Y.X. Wang -- Antisense oligonucleotide inhibitors of MDM2 oncogene expression / R. Zhang and H. Wang -- Pharmacogenetic analysis of clinically relevant genetic polymorphisms / C.M. Rose [and others] -- Gene expression microarrays / C.P. Kolbert [and others] -- Methods for isolation and genetic analysis of circulating tumor DNA in patient plasma / T. Kawaguchi, W.S. Holland and P.H. Gumerlock -- The use of early sea urchin embryos in anticancer drug testing / D. Nishioka [and others] -- PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo / A. Fredriksson and S. Stone-Elander -- Assays for in vitro and in vivo synergy / B.A. Teicher -- Flow cytometric methods for detection and quantification of apoptosis / D.P. Steensma, M. Timm and T.E. Witzig -- Assays for neoplastic cell enrichment in bone marrow samples / R. Fonseca and G.J. Ahmann.
|
| Abstract
|
:
|
With many potential molecular targets of anticancer agents already identified and many more yet to be discovered, the great challenges are now to successfully validate them, to devise relevant assays, and to translate the results into effective medicines for cancer patients. In Novel Anticancer Drug Protocols, expert basic researchers and clinicians from both industry and academia not only survey the whole arena of novel antitumor drug targets, but also present a wide-ranging selection of the key techniques currently being applied throughout anticancer drug discovery and development. Described in step-by-step detail to ensure successful results, these methods are employed in experiments involving such central topics as immunotherapy, angiogenesis, cancer metastasis, the cell cycle, signal transduction inhibitors, apoptosis, antibodies, antisense molecules, microarray gene expression analysis, flow cytometry, and PET imaging for cancer target validation. There are also proven methods for the preclinical identification of drug targets and for target validation during the clinical trials of novel agents. Each method provides background information, easy-to-follow instructions, notes on avoiding pitfalls, and alternative procedures. Eminently practical and user-friendly, Novel Anticancer Drug Protocols offers all researchers involved in cancer drug development a blend of the critical preclinical and clinical assays needed for the target validation and discovery of novel agents today.
|
| Subject
|
:
|
Antineoplastic agents-- Research-- Methodology.
|
| Subject
|
:
|
Anticancéreux-- Recherche-- Méthodologie.
|
| Subject
|
:
|
HEALTH FITNESS-- Diseases-- Cancer.
|
| Subject
|
:
|
MEDICAL-- Oncology.
|
| Subject
|
:
|
Antineoplastic Agents.
|
| Subject
|
:
|
Chemotherapie.
|
| Subject
|
:
|
Wetenschappelijke technieken.
|
| Subject
|
:
|
Antineoplastic Protocols.
|
| Subject
|
:
|
Models, Animal.
|
| Subject
|
:
|
Neoplasms-- drug therapy.
|
| Dewey Classification
|
:
|
616.99/4061
|
| LC Classification
|
:
|
RC271.C5N476 2003
|
| NLM classification
|
:
|
QV 269N937 2003
|
|
|
:
|
W1ME9616JM v.85 2003
|
| Added Entry
|
:
|
Adjei, Alex A.
|
|
|
:
|
Buolamwini, John K.
|
| |